surrogate neutralization elisa (cpass genscript)  (GenScript corporation)

Journal: Scientific Reports

Article Title: Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans

doi: 10.1038/s41598-022-15378-1

Figure Lengend Snippet: ROC curve for the in-house ELISA using optical density values.

Article Snippet: Figure 4 Correlation between the antibody titers (BAU/ml) of the in-house ELISA and the inhibition percentage by the surrogate neutralization ELISA (cPass GenScript).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans

doi: 10.1038/s41598-022-15378-1

Figure Lengend Snippet: Comparison between the in-house ELISA qualitative results and those of the automated tests Vidas SARS-CoV-2 IgG anti-RBD Biomérieux and Elecsys Anti-Nucleocapsid of SARS-CoV-2 Roche.

Article Snippet: Figure 4 Correlation between the antibody titers (BAU/ml) of the in-house ELISA and the inhibition percentage by the surrogate neutralization ELISA (cPass GenScript).

Techniques: Comparison, Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans

doi: 10.1038/s41598-022-15378-1

Figure Lengend Snippet: Correlation between the antibody titers (BAU/ml) of the in-house ELISA and the inhibition percentage by the surrogate neutralization ELISA (cPass GenScript).

Article Snippet: Figure 4 Correlation between the antibody titers (BAU/ml) of the in-house ELISA and the inhibition percentage by the surrogate neutralization ELISA (cPass GenScript).

Techniques: Enzyme-linked Immunosorbent Assay, Inhibition, Neutralization

Journal: The Journal of Infection

Article Title: Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

doi: 10.1016/j.jinf.2021.03.010

Figure Lengend Snippet: Neutralising activity in a surrogate virus neutralisation assay correlates with anti-nucleocapsid protein titre. (A)Serum samples from 30 individuals was tested for antibodies against SARS-CoV-2 nucleocapsid protein (NP) by Elecsys® Anti-SARS-CoV-2 assay. Those in red were considered positive for anti-SARS-CoV-2-NP antibodies, and are shown as such throughout the figure. (B) Serum samples from (A) were tested for neutralising activity by an ELISA-type surrogate virus neutralisation (SVN) assay. The cutoff represents the manufacturer's advised value of 20% (i.e. a 20% reduction in signal compared to the negative control). Values shown as mean ± SD. (C) Comparison between raw data from NP and SVN assays. Data was assessed by both Spearman correlation and by simple linear regression. The red line indicates the best fit linear regression line for NP-positive samples only, whilst the black line represents the best fit line for all data points. (D,E) Samples were ranked according to their NP antibody titre and neutralisation in the SVN and plotted for clarity. These ranks were then compared by simple linear regression. Data for NP-positive only samples is found in (D), whilst data for all samples is found in (E).

Article Snippet: Thus our remit was to determine whether a commercially available ELISA-type surrogate virus neutralisation kit (Genscript cPass SARS-CoV-2 Surrogate Virus Neutralization Kit), which claims to specifically measure neutralising antibodies against SARS-CoV-2 S RBD was capable of: a) detecting neutralising antibody responses in serum samples confirmed positive for antibodies against NP, b) whether those responses correlated with those determined by pseudotyped virus neutralisation assay and therefore c) whether measuring responses solely against the RBD of S protein is indicative of responses against the S protein as presented in a viral context.

Techniques: Activity Assay, Virus, Enzyme-linked Immunosorbent Assay, Negative Control, Comparison

Journal: The Journal of Infection

Article Title: Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

doi: 10.1016/j.jinf.2021.03.010

Figure Lengend Snippet: Ability of patient sera to neutralise SARS-CoV-2 pseudovirus correlates strongly with neutralisation observed in SVN assay. Data from Fig. 2 was plotted against the observed inhibition in the SVN assay and correlation assessed by Spearman correlation. Samples were then ranked according to the criteria in Fig. 2 and plotted against one another for clarity. Points in red were considered positive for anti-SARS-CoV-2-NP antibodies, and are shown as such throughout the figure. (A,B) ND 50 values were correlated against inhibition observed in the SVN assay. (A) Represents raw values, whilst (B) demonstrates ranked values from only NP-positive samples. (C,D) ND 90 values were correlated against inhibition observed in the SVN assay. (C) Represents raw values, whilst (D) demonstrates ranked values from only NP-positive samples. (E,F) Maximum Response values were correlated against inhibition observed in the SVN assay. (E) Represents raw values, whilst (F) demonstrates ranked values from only NP-positive samples. (G,H) ND 50 values were correlation against anti-NP antibody titre. (G) represents raw values, whilst (H) represents ranked values from only NP-positive samples.

Article Snippet: Thus our remit was to determine whether a commercially available ELISA-type surrogate virus neutralisation kit (Genscript cPass SARS-CoV-2 Surrogate Virus Neutralization Kit), which claims to specifically measure neutralising antibodies against SARS-CoV-2 S RBD was capable of: a) detecting neutralising antibody responses in serum samples confirmed positive for antibodies against NP, b) whether those responses correlated with those determined by pseudotyped virus neutralisation assay and therefore c) whether measuring responses solely against the RBD of S protein is indicative of responses against the S protein as presented in a viral context.

Techniques: Inhibition

Journal: The Journal of Infection

Article Title: Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

doi: 10.1016/j.jinf.2021.03.010

Figure Lengend Snippet: Surrogate neutralisation reported in SVN assay correlates with ability to prevent infection of Hela cells stably expressing ACE2. (A) SARS-CoV-2 S pseudotyped virus was incubated with a series of serum dilutions for 1 h prior to infection of Hela-ACE2 cells. Forty-eight hours post infection, luciferase activity (RLU) was readout as a measure of infection. Data shown indicates the RLU (compared to 100 for untreated pseudovirus) at the lowest serum dilution at which RLU was reduced by at least 95% (i.e. below 5). (B) Samples from NP-positive only donors or (C) samples from all donors were ranked as described based on data from and correlated with ranked performance in SVN by simple linear regression. (D,E) PVN ranking was compared to NP titre ranking for NP-positive only donors (D) or all donors (E). Points in red were considered positive for anti-SARS-CoV-2-NP antibodies, and are shown as such throughout the figure.

Article Snippet: Thus our remit was to determine whether a commercially available ELISA-type surrogate virus neutralisation kit (Genscript cPass SARS-CoV-2 Surrogate Virus Neutralization Kit), which claims to specifically measure neutralising antibodies against SARS-CoV-2 S RBD was capable of: a) detecting neutralising antibody responses in serum samples confirmed positive for antibodies against NP, b) whether those responses correlated with those determined by pseudotyped virus neutralisation assay and therefore c) whether measuring responses solely against the RBD of S protein is indicative of responses against the S protein as presented in a viral context.

Techniques: Infection, Stable Transfection, Expressing, Virus, Incubation, Luciferase, Activity Assay